Immunotherapy after surgery may keep melanoma from coming back

NCT ID NCT04013854

Ongoing Disease control Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving the immunotherapy drug nivolumab before and after surgery for stage III melanoma can help prevent the cancer from returning. About 67 adults with resectable melanoma will receive one dose of nivolumab before surgery, then after surgery they will get either nivolumab alone or a combination of nivolumab and ipilimumab for up to a year, based on how their tumor responded. The main goal is to see how long patients stay cancer-free after treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA MELANOMA STAGE III

Contacts and locations

Show contact details

Locations

Abramson Cancer Center, University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Duke Cancer Institute

Durham, North Carolina, 27710, United States
Lancaster General Hospital

Lancaster, Pennsylvania, 17601, United States